Overview
The purpose :
Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Eligibility
Inclusion Criteria:
- Confirmed MM diagnosis
- Transplant eligible patients in a first remission
- Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
- Availability of deidentified patient's demographic and clinical follow up data
- Receiving standard of care treatment
- Able to provide informed consent
Exclusion Criteria:
- Failure to meet inclusion criteria